News releases
Date
Language

Type of release


News Release date Type of release Download
 
Aktietilbagekøbsprogram May 21, 2013 Company announcement DK
Share repurchase programme May 21, 2013 Company announcement UK
Novo Nordisk rapporterer positive resultater fra det første fase 3-studie med langtidsvirkende faktor IX til behandling af hæmofili B May 17, 2013 Company announcement DK
Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B May 17, 2013 Company announcement UK
Share repurchase programme May 13, 2013 Company announcement UK
Aktietilbagekøbsprogram May 13, 2013 Company announcement DK
Novo Nordisk invests DKK 380 million in its Kalundborg plant May 06, 2013 Press release UK
Novo Nordisk investerer 380 millioner kroner i Kalundborg May 06, 2013 Press release DK
Aktietilbagekøbsprogram May 03, 2013 Company announcement DK
Share repurchase programme May 03, 2013 Company announcement UK
Novo Nordisk A/S køber B-aktier til en værdi af 2,5 mia. kr. fra Novo A/S som led i det løbende aktietilbagekøbsprogram May 03, 2013 Company announcement DK
Novo Nordisk A/S purchases B shares worth DKK 2.5 billion from Novo A/S as part of the on-going share repurchase programme May 03, 2013 Company announcement UK
Trading in Novo Nordisk shares by board members, executives and associated persons on 1 May 2013 May 02, 2013 Company announcement UK
Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 1. maj 2013 May 02, 2013 Company announcement DK
Resultat af primær drift steg med 18% i første kvartal af 2013 May 01, 2013 Company announcement DK
Increased operating profit by 18% in the first quarter of 2013 May 01, 2013 Company announcement UK
Novo Nordisk A/S : det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2013 Apr 30, 2013 Company announcement DK
Novo Nordisk A/S : Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2013 Apr 30, 2013 Company announcement UK
Share repurchase programme Apr 30, 2013 Company announcement UK
Aktietilbagekøbsprogram Apr 30, 2013 Company announcement DK
10,000 children’s lives improved through new clinics Apr 25, 2013 Featured story UK
Aktietilbagekøbsprogram Apr 22, 2013 Company announcement DK
Share repurchase programme Apr 22, 2013 Company announcement UK
Reduction of the share capital Apr 22, 2013 Company announcement UK
Nedsættelse af aktiekapitalen Apr 22, 2013 Company announcement DK
Aktietilbagekøbsprogram Apr 15, 2013 Company announcement DK
Share repurchase programme Apr 15, 2013 Company announcement UK
Diabetes on the agenda in Mexico Apr 09, 2013 Featured story UK
Apr 09, 2013 Featured story DK
Share repurchase programme Apr 08, 2013 Company announcement UK
Aktietilbagekøbsprogram Apr 08, 2013 Company announcement DK
Status vedrørende Novo Nordisks beholdning af egne aktier (31. marts 2013) Apr 02, 2013 Company announcement DK
Status regarding Novo Nordisk's holding of its own shares (31 March 2013) Apr 02, 2013 Company announcement UK
Novo Nordisk A/S - Share repurchase programme Apr 02, 2013 Company announcement UK
Novo Nordisk A/S - aktietilbagekøbsprogram Apr 02, 2013 Company announcement DK
Share repurchase programme Mar 25, 2013 Company announcement UK
Aktietilbagekøbsprogram Mar 25, 2013 Company announcement DK
Den langsigtede aktiebaserede incitamentsordning for Senior Management Board for 2013 Mar 21, 2013 Company announcement DK
2013 long-term, share based incentive programme for the Senior Management Board Mar 21, 2013 Company announcement UK
Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S Mar 20, 2013 Company announcement DK
Resolutions from the Annual General Meeting of Novo Nordisk A/S Mar 20, 2013 Company announcement UK
6,900 applications for 48 graduate positions Mar 19, 2013 Featured story UK
Mar 19, 2013 Featured story DK
Aktietilbagekøbsprogram Mar 18, 2013 Company announcement DK
Share repurchase programme Mar 18, 2013 Company announcement UK
People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial Mar 18, 2013 Company announcement UK
Type 2-diabetikere opnår 6% vægttab med liraglutid 3 mg i fase 3a-fedmestudie Mar 18, 2013 Company announcement DK
Novo Nordisk A/S : share repurchase programme Mar 11, 2013 Company announcement UK
Novo Nordisk A/S : aktietilbagekøbsprogram Mar 11, 2013 Company announcement DK
In Nigeria, a new project prompts easier insulin access Mar 05, 2013 Featured story UK
Novo Nordisk A/S - Share repurchase programme Mar 04, 2013 Company announcement UK
Novo Nordisk A/S - aktietilbagekøbsprogram Mar 04, 2013 Company announcement DK
Share repurchase programme Feb 25, 2013 Company announcement UK
Aktietilbagekøbsprogram Feb 25, 2013 Company announcement DK
Notice for the Annual General Meeting of Novo Nordisk A/S Feb 22, 2013 Company announcement UK
Indkaldelse til ordinær generalforsamling i Novo Nordisk A/S Feb 22, 2013 Company announcement DK
Novo Nordisk A/S : Share repurchase programme Feb 18, 2013 Company announcement UK
Novo Nordisk A/S : aktietilbagekøbsprogram Feb 18, 2013 Company announcement DK
Novo Nordisk lancerer NovoSeven® med engangssprøjte til hurtig standsning af blødninger Feb 14, 2013 Press release DK
Novo Nordisk launches NovoSeven® with pre-filled syringe for fast bleeding control Feb 14, 2013 Press release UK
Aktietilbagekøbsprogram Feb 11, 2013 Company announcement DK
Share repurchase programme Feb 11, 2013 Company announcement UK
Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 8. februar 2013. Feb 11, 2013 Company announcement DK
Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2013 Feb 11, 2013 Company announcement UK
Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® Feb 10, 2013 Company announcement UK
Novo Nordisk modtager Complete Response Letter i USA vedrørende Tresiba® og Ryzodeg® Feb 10, 2013 Company announcement DK
Press release: Novo Nordisk files annual report with the SEC Feb 07, 2013 Company announcement UK
Novo Nordisk-kommentar vedr. skattebetaling i Danmark Feb 05, 2013 Press release DK
Feb 05, 2013 Press release UK
Previously announced FDA Warning Letter published Feb 05, 2013 Company announcement UK
Det tidligere omtalte Warning Letter fra FDA publiceret Feb 05, 2013 Company announcement DK
Novo Nordisk publishes its 2012 Annual Report Feb 04, 2013 Press release UK
Novo Nordisk har publiceret sin årsrapport for 2012 Feb 04, 2013 Press release DK
Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 31. januar 2013 Feb 01, 2013 Company announcement DK
Trading in Novo Nordisk shares by board members, executives and associated persons on 31 January 2013 Feb 01, 2013 Company announcement UK
Novo Nordisks resultat af primær drift steg med 32% i 2012 Jan 31, 2013 Company announcement DK
Novo Nordisk increased operating profit by 32% in 2012 Jan 31, 2013 Company announcement UK
Novo Nordisk A/S - aktietilbagekøbsprogram Jan 30, 2013 Company announcement DK
Novo Nordisk A/S - Share repurchase programme Jan 30, 2013 Company announcement UK
Tresiba® and Ryzodeg® receive marketing authorisations in Europe Jan 21, 2013 Company announcement UK
Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa Jan 21, 2013 Company announcement DK
Aktietilbagekøbsprogram Jan 21, 2013 Company announcement DK
Share repurchase programme Jan 21, 2013 Company announcement UK
Aktietilbagekøbsprogram Jan 14, 2013 Company announcement DK
Share repurchase programme Jan 14, 2013 Company announcement UK
Novo Nordisk A/S - Share repurchase programme Jan 07, 2013 Company announcement UK
Aktietilbagekøbsprogram Jan 07, 2013 Company announcement DK
Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 December 2012) Jan 02, 2013 Company announcement UK
Novo Nordisk A/S: Status vedrørende Novo Nordisks beholdning af egne aktier (31. december 2012) Jan 02, 2013 Company announcement DK
Novo Nordisk A/S - Share repurchase programme Jan 02, 2013 Company announcement UK
Novo Nordisk A/S - aktietilbagekøbsprogram Jan 02, 2013 Company announcement DK
Ryzodeg® (insulin degludec/insulin aspart) approved in Japan Dec 25, 2012 Company announcement UK
Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan Dec 25, 2012 Company announcement DK
Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling Dec 19, 2012 Company announcement DK
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development Dec 19, 2012 Company announcement UK
Novo Nordisk A/S : aktietilbagekøbsprogram Dec 17, 2012 Company announcement DK
Novo Nordisk A/S : Share repurchase programme Dec 17, 2012 Company announcement UK
Novo Nordisk A/S - aktietilbagekøbsprogram Dec 10, 2012 Company announcement DK
Novo Nordisk A/S - Share repurchase programme Dec 10, 2012 Company announcement UK
Novo Nordisk A/S : Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 5. december 2012. Dec 06, 2012 Company announcement DK
Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 5 December 2012 Dec 06, 2012 Company announcement UK
Moody’s opgraderer Novo Nordisk til ‘A1’ Dec 05, 2012 Press release DK
Novo Nordisk upgraded to ‘A1’ by Moody’s Dec 05, 2012 Press release UK
Novo Nordisk to create the world's first all-diabetes professional cycling team Dec 04, 2012 Press release UK
Novo Nordisk etablerer verdens første professionelle diabetescykelhold Dec 04, 2012 Press release DK
Novo Nordisk A/S: Share repurchase programme Dec 03, 2012 Company announcement UK
Novo Nordisk A/S: aktietilbagekøbsprogram Dec 03, 2012 Company announcement DK
Families carry a major burden of the diabetes pandemic, according to new results from global study Dec 03, 2012 Press release UK
Diabetes har omkostninger for hele familien, viser ny global undersøgelse Dec 03, 2012 Press release DK
Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan Dec 03, 2012 Company announcement UK
Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite Dec 03, 2012 Company announcement DK
Data show patients with type 2 diabetes are likelier to reach HbA1c target below 7% during 26 weeks treatment with Victoza(R) (liraglutide) compared with sitagliptin or exenatide BID Nov 27, 2012 Press release UK
Data viser, at patienter med type 2-diabetes har større sandsynlighed for at nå målet om et langtidsblodsukker på under 7% i løbet af 26 ugers behandling med Victoza® (liraglutid) end med sitagliptin eller exenatid BID Nov 27, 2012 Press release DK
Novo Nordisk A/S : Share repurchase programme Nov 26, 2012 Company announcement UK
Novo Nordisk A/S : aktietilbagekøbsprogram Nov 26, 2012 Company announcement DK
Enter search word